bluebird bio Sells Second Priority Review Voucher for $95 Million

Author's Avatar
Jan 06, 2023

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million.